← All trials
NCT04756648
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Mar 10, 2021
- Primary completion
- Apr 30, 2022
- Completion date
- Apr 30, 2023
- First posted
- Feb 16, 2021
- Last posted
- Aug 20, 2021
- Enrollment
- 21
- Arms / groups
- 1 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Zhejiang UniversityLead sponsor
- Zhejiang UniversityReponsible party - principal investigator
- Zhejiang UniversityOverall official - principal investigator
- CARsgen Therapeutics, Ltd.Collaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.